Jang Won Sik, Cho Kang Su, Kim Myung Soo, Yoon Cheol Yong, Kang Dong Hyuk, Kang Yong Jin, Jeong Won Sik, Ham Won Sik, Choi Young Deuk
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Oncotarget. 2017 Feb 14;8(7):11778-11787. doi: 10.18632/oncotarget.14349.
The pretreatment neutrophil-to-lymphocyte ratio has prognostic value after radical prostatectomy for treating localized prostate cancer. However, the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in this population. We investigated the prognostic significance of early postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer.
We retrospectively reviewed clinical data from 2,302 patients with localized prostate cancer who underwent radical prostatectomy at our institution between years 2000 and 2010. Only patients with pre- and postoperative complete blood counts with differential results were included. Patients who received neoadjuvant or postoperative adjuvant treatment and those without adequate medical records were excluded. Kaplan-Meier analyses were performed to analyze biochemical recurrence-free survival and overall survival rates. Univariate and multivariate Cox regression models were used for each endpoint.
Kaplan-Meier curves showed that high postoperative neutrophil-to-lymphocyte ratio (>3.5) was significantly associated with decreased biochemical recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the univariate and multivariate Cox regression analyses, high postoperative neutrophil-to-lymphocyte ratio was a significant predictor of biochemical recurrence (hazard ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033).
Our results demonstrate that postoperative neutrophil-to-lymphocyte ratio is an independent factor for biochemical recurrence and overall survival in patients who underwent radical prostatectomy for prostate cancer. These findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool for stratifying high-risk patients and facilitating choices of postoperative therapy in patients with prostate cancer.
对于局限性前列腺癌患者，术前中性粒细胞与淋巴细胞比值在根治性前列腺切除术后具有预后价值。然而，该人群术后中性粒细胞与淋巴细胞比值的应用尚未得到评估。我们研究了前列腺癌根治术后早期中性粒细胞与淋巴细胞比值的预后意义。
我们回顾性分析了2000年至2010年间在我院接受根治性前列腺切除术的2302例局限性前列腺癌患者的临床资料。仅纳入术前和术后有完整血常规及分类结果的患者。排除接受新辅助或术后辅助治疗的患者以及病历资料不全的患者。采用Kaplan-Meier分析来分析无生化复发生存率和总生存率。对每个终点使用单因素和多因素Cox回归模型。
Kaplan-Meier曲线显示，术后高中性粒细胞与淋巴细胞比值（>3.5）与无生化复发生存率降低（p = 0.009）和总生存率降低（p = 0.010）显著相关。在单因素和多因素Cox回归分析中，术后高中性粒细胞与淋巴细胞比值是生化复发（风险比1.270，p = 0.008）和总生存（风险比1.437，p = 0.033）的显著预测因素。
我们的结果表明，术后中性粒细胞与淋巴细胞比值是接受前列腺癌根治术患者生化复发和总生存的独立因素。这些发现提示，中性粒细胞与淋巴细胞比值可能是对高危患者进行分层以及辅助前列腺癌患者术后治疗选择的潜在有价值工具。
